Skip to main content
Figure 1 | Molecular Cancer

Figure 1

From: A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy

Figure 1

Patient flow through the study. Patient flow through the study: 1Including adverse events relating to disease progression; 2Unrelated to disease progression; 3Includes one patient in each group who discontinued due to study closure; 4Efficacy was analyzed on the all-randomized set; however, one patient, randomized to placebo, did not receive any study treatment, had no post-baseline tumor assessments, and had data missing for the date of randomization at the time of database closure. Because time-to-event analyses required a randomization date, this patient could not be included in these analyses, including the primary endpoint.

Back to article page